

90% omega-3-acid ethyl esters (Omacor<sup>®</sup>)  
(No. 15/02)

---

Solvay Healthcare Ltd  
Summary of Recommendation

*Indication: Secondary prevention after MI*

8 November 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Acceptable for general use within NHS Scotland as an additional treatment for the secondary prevention of myocardial infarction.

**RECOMMENDATION**

Whilst cost effectiveness appears to be within generally acceptable limits, NHS Boards will recognise that there are now a number of established interventions for this indication. The priority given to this agent needs to be considered alongside the implementation of other effective approaches to secondary prevention of cardiovascular disease, always keeping in mind alternative dietary methods of obtaining fish oil supplementation.

Professor David H Lawson  
Chairman